Literature DB >> 27479195

Comparison of biomarker expression between proximal and distal colorectal adenomas: The Tennessee-Indiana Adenoma Recurrence Study.

Timothy Su1,2, M Kay Washington3, Reid M Ness4, Douglas K Rex5, Walter E Smalley4, Thomas M Ulbright6, Qiuyin Cai1,2, Wei Zheng1,2, Martha J Shrubsole1,2.   

Abstract

It is unclear if proximal and distal traditional adenomas present with differences in molecular events which contribute to cancer heterogeneity by tumor anatomical subsite. Participants from a colonoscopy-based study (n = 380) were divided into subgroups based on the location of their most advanced adenoma: proximal, distal, or "equivalent both sides." Eight biomarkers in the most advanced adenomas were evaluated by immunohistochemistry (Ki-67, COX-2, TGFβRII, EGFR, β-catenin, cyclin D1, c-Myc) or TUNEL (apoptosis). After an adjustment for pathological features, there were no significant differences between proximal and distal adenomas for any biomarker. Conversely, expression levels did vary by other features, such as their size, villous component, and synchronousness. Large adenomas had higher expression levels of Ki-67(P < 0.001), TGFβRII (P < 0.0001), c-Myc (P < 0.001), and cyclin D1 (P < 0.001) in comparison to small adenomas, and tubulovillous/villous adenomas also were more likely to have similar higher expression levels in comparison to tubular adenomas. Adenoma location is not a major determinant of the expression of these biomarkers outside of other pathological features. This study suggests similarly important roles of Wnt/β-catenin and TGF-β pathways in carcinogenesis in both the proximal and distal colorectum.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  biomarkers; colorectal adenoma; distal; immunohistochemistry; proximal; β-catenin

Mesh:

Substances:

Year:  2016        PMID: 27479195      PMCID: PMC5541935          DOI: 10.1002/mc.22533

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  85 in total

1.  Interaction between Wnt and TGF-beta signalling pathways during formation of Spemann's organizer.

Authors:  M Nishita; M K Hashimoto; S Ogata; M N Laurent; N Ueno; H Shibuya; K W Cho
Journal:  Nature       Date:  2000-02-17       Impact factor: 49.962

2.  Abnormal expression of Endoglin and its receptor complex (TGF-β1 and TGF-β receptor II) as early angiogenic switch indicator in premalignant lesions of the colon mucosa.

Authors:  Graziella Bellone; Claudia Gramigni; Barbara Vizio; Francesco A Mauri; Adriana Prati; Dino Solerio; Luca Dughera; Enrico Ruffini; Guido Gasparri; Michele Camandona
Journal:  Int J Oncol       Date:  2010-11       Impact factor: 5.650

3.  A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers.

Authors:  Siwanon Jirawatnotai; Yiduo Hu; Wojciech Michowski; Joshua E Elias; Lisa Becks; Frederic Bienvenu; Agnieszka Zagozdzon; Tapasree Goswami; Yaoyu E Wang; Alan B Clark; Thomas A Kunkel; Tanja van Harn; Bing Xia; Mick Correll; John Quackenbush; David M Livingston; Steven P Gygi; Piotr Sicinski
Journal:  Nature       Date:  2011-06-08       Impact factor: 49.962

Review 4.  Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers.

Authors:  Bryan D White; Andy J Chien; David W Dawson
Journal:  Gastroenterology       Date:  2011-12-08       Impact factor: 22.682

5.  Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival.

Authors:  Frank Benedix; Rainer Kube; Frank Meyer; Uwe Schmidt; Ingo Gastinger; Hans Lippert
Journal:  Dis Colon Rectum       Date:  2010-01       Impact factor: 4.585

6.  Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study.

Authors:  Syed K Mohsin; Heidi Weiss; Thomas Havighurst; Gary M Clark; Melora Berardo; Le D Roanh; Ta V To; Zhang Qian; Zho Qian; Richard R Love; D Craig Allred
Journal:  Mod Pathol       Date:  2004-12       Impact factor: 7.842

7.  Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry.

Authors:  George Deeb; Jianmin Wang; Nithya Ramnath; Harry K Slocum; Sam Wiseman; Amy Beck; Dongfeng Tan
Journal:  Mod Pathol       Date:  2004-04       Impact factor: 7.842

Review 8.  The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment.

Authors:  Alexander Greenhough; Helena J M Smartt; Amy E Moore; Heather R Roberts; Ann C Williams; Christos Paraskeva; Abderrahmane Kaidi
Journal:  Carcinogenesis       Date:  2009-01-09       Impact factor: 4.944

9.  Gastrin and colorectal cancer: a prospective study.

Authors:  C M Thorburn; G D Friedman; C J Dickinson; J H Vogelman; N Orentreich; J Parsonnet
Journal:  Gastroenterology       Date:  1998-08       Impact factor: 22.682

10.  β-catenin overexpression in the nucleus predicts progress disease and unfavourable survival in colorectal cancer: a meta-analysis.

Authors:  Zhigang Chen; Xin He; Minyue Jia; Yang Liu; Dihong Qu; Dang Wu; Pin Wu; Chao Ni; Zhigang Zhang; Jun Ye; Jinghong Xu; Jian Huang
Journal:  PLoS One       Date:  2013-05-24       Impact factor: 3.240

View more
  2 in total

1.  ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER?

Authors:  Leticia Elizabeth Augustin Czeczko; Carmen Australia Paredes Marcondes Ribas; Nicolau Gregori Czeczko; Thelma Larocca Skare; Camila Kienen Yamakawa; Guilherme Gionedis; Cecilia Vasconcelos; Fabiola Pabst Bremer; Diogo Francesco Castoldi; Martin Gasser; Ana Maria Waaga-Gasser
Journal:  Arq Bras Cir Dig       Date:  2021-03-22

2.  N-3 Long Chain Fatty Acids Supplementation, Fatty Acids Desaturase Activity, and Colorectal Cancer Risk: A Randomized Controlled Trial.

Authors:  Harvey J Murff; Martha J Shrubsole; Qiuyin Cai; Timothy Su; Jennings H Dooley; Sunny S Cai; Wei Zheng; Qi Dai
Journal:  Nutr Cancer       Date:  2021-07-22       Impact factor: 2.816

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.